Immunome
IMNM
Immunome (IMNM) earnings history
Most recent quarter
- Fiscal period
- Q2 2025
- Period end
- Jun 30, 2025
- EPS actual
- −$0.50
- EPS estimate
- −$0.52
- EPS surprise
- +3.23%
- Revenue surprise
- +381.80%
- Revenue
- $4.0M
- Revenue estimate
- $833,333.00
- Reported
- Aug 6, 2025
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2025 | Aug 6, 2025 | −$0.52 | −$0.50 | +3.23% | $4.0M | SEC |
| Q1 2025 | May 12, 2025 | −$0.63 | −$0.52 | +18.08% | $2.9M | SEC |
| Q4 2024 | Mar 19, 2025 | −$0.64 | −$1.11 | −73.22% | $2.7M | SEC |
| Q3 2024 | Nov 13, 2024 | −$0.55 | −$0.78 | −41.46% | $2.9M | SEC |
| Q2 2024 | Aug 12, 2024 | −$0.38 | −$0.60 | −58.14% | $2.4M | SEC |
| Q1 2024 | May 14, 2024 | −$0.68 | −$2.51 | −269.12% | $1.0M | SEC |
| Q4 2023 | Mar 28, 2024 | −$0.27 | −$4.21 | −1440.43% | $3.8M | SEC |
| Q3 2023 | Nov 9, 2023 | −$0.17 | −$0.36 | −111.76% | $3.6M | SEC |
| Q2 2023 | Aug 9, 2023 | −$0.16 | −$0.46 | −187.50% | $4.3M | SEC |
| Q1 2023 | May 5, 2023 | $0.59 | −$0.35 | −159.83% | $2.4M | SEC |
| Q4 2022 | Mar 16, 2023 | −$0.68 | −$0.64 | +5.19% | $0.00 | SEC |
| Q3 2022 | Nov 14, 2022 | −$0.76 | −$0.75 | +1.32% | $0.00 | — |
| Q2 2022 | Aug 5, 2022 | −$0.93 | −$0.74 | +20.43% | $0.00 | — |
| Q1 2022 | May 12, 2022 | −$0.69 | −$0.96 | −39.13% | $0.00 | — |
| Q4 2021 | Mar 28, 2022 | −$0.81 | −$0.65 | +19.75% | $0.00 | — |
| Q3 2021 | Nov 15, 2021 | −$0.51 | −$0.65 | −28.71% | $0.00 | — |
| Q2 2021 | Aug 16, 2021 | −$0.39 | −$0.46 | −17.95% | $0.00 | — |
| Q1 2021 | May 12, 2021 | −$0.41 | −$0.37 | +9.76% | $0.00 | — |
| Q4 2020 | Mar 25, 2021 | −$0.29 | −$0.40 | −37.93% | $0.00 | — |
Quarterly revenue
Frequently asked questions
When did Immunome (IMNM) last report earnings?
Immunome last reported on Aug 6, 2025, covering fiscal Q2 2025.
Did IMNM beat earnings estimates?
Yes. Immunome reported EPS of −$0.50 for Q2 2025 against a −$0.52 estimate — a 3.23% beat.
How much revenue did IMNM report last quarter?
Immunome reported $4.0M in revenue for Q2 2025, against a consensus estimate of $833,333.00.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.